NA
A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714
What was tested
Treatment tested
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Percent change in the extent of 18FDPA714 positive voxels in the total white matter from baseline to month 24 in the whole cohort of MS patients.
Other measures (1)
- Percent change in extent of 18FDPA714 positive voxels in normal appearing white matter between baseline and months 6 (short-term) and 24 (long-term) in the whole cohort, in RMS cohort (global and splitted in RRMS and RMS having reached the SPMS phase) and in PPMS cohort
Loading reviews and guidelines…
Related trials
- An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Pr
Early phase 1 · Not yet recruiting
Still running
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatme
Not a drug-phase study · Recruiting
Still running
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agon
Recruiting
Still running
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations
Phase 2 · Running, not recruiting
Still running
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharma
Phase 4 · Running, not recruiting
Still running
- The use of therapeutic monitoring of ocrelizumab serum concentrations
Phase 4 · Recruiting
Still running
History
- In scope changed from true to false
Started
Jul 2018